Vesper Medical develops the Vesper DUO Venous Stent System®, engineered to address the anatomical challenges of the deep venous system in patients with Chronic Venous Insufficiency (CVI). This next-generation stent portfolio reduces the need for multiple stent types in the iliofemoral segment, streamlining treatment and improving patient outcomes.
Funding
$37M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GHFounders
Product
Problem
Chronic Venous Insufficiency (CVI) poses anatomical challenges in the deep venous system, often requiring multiple stent types during iliofemoral segment procedures. The need to "mix and match" stents can complicate treatment and potentially impact patient outcomes.
Solution
The Vesper DUO Venous Stent System is engineered to address the anatomical complexities of the deep venous system in CVI patients. This next-generation stent portfolio is designed to reduce the necessity for multiple stent types in the iliofemoral segment, streamlining the treatment process. The system includes DUO-HYBRID and DUO-EXTEND stents, offering physicians versatile options to treat a broad range of patient anatomies. The ongoing VIVID clinical trial is evaluating the system's performance in adult CVI patients eligible for venous stenting in their iliac or common femoral veins.
Target Audience
The primary target audience includes vascular surgeons, interventional radiologists, and other physicians specializing in the treatment of Chronic Venous Insufficiency and deep venous disease.
Features
- DUO-HYBRID stent designed for complex anatomies requiring both flexibility and radial force.
- DUO-EXTEND stent engineered for precise placement and optimal wall apposition in longer lesions.
- Stent architecture intended to minimize the need for "mixing and matching" of different stent types.
- Designed to improve procedural efficiency and reduce overall treatment complexity.
- VIVID clinical trial data being collected to assess long-term safety and efficacy.